Acknowledgments
RIMD
DISEASES, LARSEN
We thank study volunteers and their families for their participation in the study and acknowledge the support of Schiphra Director Marie Claire Traore and staff at various departments, notably Moussa Ouédraogo; the Local Safety Monitor and the Independent Safety Monitoring Committee (Kwaku Poku Asante, Marceline T. Yaméogo, Meta Roestenberg,Yoshio Hirota, and Tomomi Yamada) for their support. Guidance of the Secretary-General Francine Ouedraogo (Ministry of Health), the Japanese embassy in Ouagadougou (Ambassador Tamotsu Ikezaki, Tamaoki Shiori, Hideo Matsubara, and Junji Yamashita), IRSS Director Sylvin Ouedraogo; regulatory authorities and ethics committees in Burkina Faso, UK, Japan; and the Independent Scientific Advisory Committee (Carole Long, Mahamadou Thera, and Takafumi Tsuboi). We thank Dr. Sophie Sarrassat (LSHTM) for the preparation of reports to be reviewed by ISMC. We also gratefully acknowledge advice and guidance from Takahiro Tougan, Nobuko Arisue, Masanori Yagi, Yasunari Haseda (RIMD); Ole Olesen, Stefan Jungbluth (EVI); the clinical trial assistance of Lydia Dabré and Ernestine Yougbare (GRAS); laboratory assistance of Hideko Yoshikawa, Sawako Itagaki (RIMD); the administration and logistical support of Mohamadou Siribié and Nadège Kinda (GRAS), Sten Larsen Finnsson and Thorsten Kohaut (EVI), and Kumiko Tai (RIMD). Vaccine manufacture and supply was supported and undertaken by The Research Foundation for Microbial Diseases of Osaka University (BIKEN); GeneDesign, Inc. and Toyobo Co., Ltd, Japan. Additional trial logistics, support and all other activities are duly acknowledged from Masanori Osakabe, Takako Aburada, Satoru Murayama, and Motomichi Kouno (NPC).